Arena Pharmaceuticals (LTS:0S54) FCF Margin % : -224,127.78% (As of Dec. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Arena Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Arena Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2021 was $-121.03 Mil. Arena Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was $0.05 Mil. Therefore, Arena Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2021 was -224,127.78%.

As of today, Arena Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Arena Pharmaceuticals's FCF Margin % or its related term are showing as below:

LTS:0S54' s FCF Margin % Range Over the Past 10 Years
Min: -968525.93 Med: 0 Max: 0
Current: -968525.93

LTS:0S54's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -147.71 vs LTS:0S54: -968525.93

Arena Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Arena Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals FCF Margin % Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

-312.86

-739.59

69.92

-110,944.83

-968,525.93

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
FCF Margin %	Get a 7-Day Free Trial															-287,889.19	-	-	-	-224,127.78

Competitive Comparison of Arena Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Arena Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arena Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's FCF Margin % falls into.

Arena Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Arena Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-523.004	/	0.054
	=	-968,525.93 %

Arena Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2021 )	/	Revenue (Q: Dec. 2021 )
	=	-121.029	/	0.054
	=	-224,127.78 %

Arena Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (LTS:0S54) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (LTS:0S54) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (LTS:0S54) Headlines

No Headlines